Trevi Therapeutics Inc

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Trevi Therapeutics reports transformative year with strong financial position

Trevi Therapeutics' strong performance in 2022, backed by positive trial results and financial stability, sets the stage for continued growth.
While facing challenges such as potential delays and increased expenses, Trevi's strategic planning and diverse opportunities position the company for success.
By leveraging its strengths in clinical development and upcoming data releases, Trevi aims to build scientific evidence and attract potential partners.
Overall, Trevi's focus on advancing its pipeline and showcasing trial results highlights its commitment to addressing unmet medical needs.

Trevi Therapeutics advances Haduvio trials, navigates regulatory challenges for growth

Trevi Therapeutics showcased progress in Haduvio's clinical development and financial stability despite a net loss.
The company faces challenges in dosing strategies, patent coverage, and regulatory hurdles but is poised for growth through strategic initiatives.

Trevi Therapeutics advances Haduvio in chronic cough, overcomes financial hurdles

Trevi Therapeutics is progressing with Haduvio's development in chronic cough indications
Financially, the company is managing its resources prudently and eliminating debt
Challenges persist with study delays due to supply shortages, but opportunities for growth are evident

Trevi Therapeutics advances Haduvio trials amidst financial stability

Trevi Therapeutics' financials show resilience with a focus on clinical advancements.
Challenges in trial planning and FDA outcomes require strategic navigation.
Opportunities for growth lie in upcoming trials and conference participation.
Overall, Trevi Therapeutics is positioned for continued progress and innovation.

Trevi Therapeutics advances novel cough treatments amidst financial challenges

Trevi Therapeutics is advancing innovative treatments for refractory chronic cough. Despite financial challenges, the company's strong cash position and ongoing clinical trials position it well for future growth.

Trevi Therapeutics reports Q1 loss, progresses in clinical trials

Trevi Therapeutics faces challenges with timelines for top line data in ongoing trials but holds promise in clinical development.
The company's financial performance reflects increased R&D expenses but maintains a strong cash position for future growth.

Trevi Therapeutics reports Q2 loss, advances in key trials

Trevi Therapeutics' Q2 2024 performance reflects ongoing investment in research with a net loss of $12.4 million and R&D expenses at $10 million.
Management's strategic focus on IPF and RCC trials, along with new leadership appointments and study initiations, underpin the company's commitment to therapeutic advancements.
While facing challenges like enrollment imbalances and financial pressures, Trevi Therapeutics remains poised for growth with upcoming data readouts and a strong research pipeline.

Trevi Therapeutics reports Q3 loss, eyes upcoming milestones and trials

Trevi Therapeutics is navigating increased R&D expenses, with a strong cash position and clear focus on upcoming data milestones. Analyst inquiries and ongoing trials present challenges, while opportunities lie in defining patient populations and regulatory decisions post-NDA submission.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Trevi Therapeutics Inc. TRVI, +1.00% jumped 38.1% in premarket trading on Wednesday after the company said its experimental treatment for prurigo nodularis, a type of inflammatory skin disease, met the primary endpoint in a Phase 2b/3 clinical trial. If approved, the oral treatment would be the first therapy to treat prurigo nodularis, Trevi said.

Trevi's stock gains 38% after announcing positive data for skin-disease drug

Haduvio (oral nalbuphine ER) demonstrated statistically significant results on the primary efficacy endpoint as measured  by a 4-point reduction in the Worst Itch – Numerical Rating Scale (WI-NRS) (p=0.0157) The trial also met key secondary endpoints, with a safety profile consistent with prior studies Topline data will be presented by management and study investigator, Jennifer L Parish, MD, on a conference call and webcast on June 29, 2022, at 8:30 am EDT NEW HAVEN, Conn. , June 29, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced positive results from its Phase 2b/3 P ruritus R elief through I tch- S cratch M odulation (PRISM) trial of Haduvio in treating prurigo nodularis.

Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis

NEW HAVEN, Conn. , June 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that Jennifer Good, President and CEO, will deliver a company presentation at 2022 BIO International Convention.

Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Bill Forbes – Chief Development Officer Conference Call Participants Serge Belanger – Needham & Company Annabel Samimy – Stifel Nathan Weinstein – Aegis Capital Operator Good afternoon, and welcome to the Trevi Therapeutics First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

Trevi Therapeutics' (TRVI) CEO Jennifer Good on Q1 2022 Results - Earnings Call Transcript

Accelerated planning for next phase of development of Haduvio for the treatment of chronic cough in IPF based on results from statistically significant interim analysis of Phase 2 CANAL Trial Completed enrollment for Phase 2b/3 PRISM study in chronic pruritus in PN with data expected Q2 2022 Completed $55 million private placement in April 2022, proceeds will be used to fund clinical development of Haduvio for the treatment of chronic cough in IPF patients Management to host conference call and webcast today at 4:30 p.m. EDT NEW HAVEN, Conn.

Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update

Conference Call and Webcast to be Held at 4:30 p.m. EDT NEW HAVEN, Conn.

Trevi Therapeutics to Report Q1 2022 Financial Results and Provide a Corporate Update on May 12, 2022

NEW HAVEN, Conn. , May 3, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that senior management will present at the following May meetings: LifeSci Partners Immunology & Inflammation Symposium Date: Wednesday, May 11, 2022 Fireside chat presenters: Jennifer Good, President and CEO, and Dr. Bill Forbes, CDO Time: 2:00 p.m.

Trevi Therapeutics to Present at Upcoming May Meetings

Does Trevi Therapeutics, Inc. (TRVI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Trevi Therapeutics, Inc. (TRVI) is a Great Choice

UPDATE: Fireside chat will be held on Tuesday, April 12, 2022, from 10:15 a.m. to 10:55 a.m.

Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference

Trevi Therapeutics (TRVI) stock is slipping on Friday but that's only after the biopharmaceutical company saw a massive rally yesterday. The post Why Is Trevi Therapeutics (TRVI) Stock On the Move Today?

Why Is Trevi Therapeutics (TRVI) Stock On the Move Today?

Trevi Therapeutics Inc (NASDAQ: TRVI) has announced a private placement of 4.5 million priced at $1.90 per share and pre-funded warrants to purchase up to 24.4 million shares at $1.899 per warrant. The gross proceeds are approximately $55 million.

Trevi Therapeutics Shares Gain On Raising $55M Via Equity

Proceeds To Fund the Development of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis NEW HAVEN, Conn. , April 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that it has entered into a definitive agreement with certain healthcare-focused institutional investors for the purchase, in a private placement priced at-the-market under Nasdaq rules, of (i) 4,580,526 shares of common stock at a purchase price of $1.90 per share, and (ii) pre-funded warrants to purchase up to an aggregate of 24,379,673 shares of common stock at a purchase price of $1.899 per warrant, for gross proceeds of approximately $55 million.

Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market

Webinar will be held on Wednesday, March 30, 2022, from 8:00 a.m. to 9:00 a.m.

Trevi Therapeutics Hosting Key Opinion Leader Webinar on the Seriousness of Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

Trevi Therapeutics, Inc.'s (TRVI) CEO Jennifer Good on Q4 2021 Results - Earnings Call Transcript

Interim Analysis in Phase 2 CANAL Trial Showed Primary Efficacy Endpoint of Cough Reduction in Idiopathic Pulmonary Fibrosis was Highly Statistically Significant (p-value less than 0.0001)  Enrollment Ended Early Trevi to host a KOL call "Understanding the Seriousness of Chronic Cough in IPF Patients" on March 30, 2022, from 8:00 to 9:00 am EDT Phase 2b/3 PRISM Trial (Chronic Pruritus in PN) Completed Enrollment Top-Line Data Readout Expected Second Quarter of 2022 Management to Host Conference Call and Webcast Today at 4:30 p.m. EDT NEW HAVEN, Conn.

Trevi Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Business Update

Previously Announced Statistically Significant Interim Analysis Established Proof of Concept (p-value less than 0.0001) Efficacy and Safety Data Expected on the Full Set of Subjects in Third Quarter 2022 NEW HAVEN, Conn. , March 15, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER).

Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough

NEW HAVEN, Conn., March 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER).

Trevi Therapeutics to Report Q4 and Year End 2021 Financial Results and Provide a Corporate Update on March 17, 2022

NEW HAVEN, Conn., Feb. 24, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced positive interim analysis results of the Phase 2 C ough A nd NAL buphine (CANAL) trial of its investigational therapy Haduvio™ (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough, establishing proof of concept.

Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

Trevi Therapeutics Inc (NASDAQ: TRVI) has announced positive interim analysis results from Phase 2 CANAL trial of Haduvio (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough. The company conducted a statistical analysis to assess the.

Why Are Trevi Therapeutics Shares Surging During Premarket Thursday?

NEW HAVEN, Conn., Feb. 1, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions.

Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN

Trevi Therapeutics, Inc. (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Trevi Therapeutics, Inc. (TRVI) Could be Great Choice for a Bottom Fisher

NEW HAVEN, Conn. , Jan. 5, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions.

Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications

NEW HAVEN, Conn. , Dec. 16, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions.

Trevi Therapeutics to Attend Multiple Conferences in January 2022

LaZBoy

Oncolytics Biotech, Inc.

Sunopta

Tapestry

Bet on top-ranked stocks STKL, LZB, ONCY, TPR and TRVI that have rising P/E to realize outsized gains.

5 Stocks With Rising P/E Are Good Buys

Trevi Therapeutics, Inc. (TRVI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

News for Trevi Therapeutics Inc Stock (TRVI)